David Beauvais

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 343 citations · Full text

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy et al. · Blood · 2022 · 131 citations · Full text

Aggressive B-cell Lymphoma, Immunology, Pathology +18

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay, Pedro Castro, Adel Maamar et al. · The Lancet Haematology · 2021 · 91 citations

Clinical Immunology, Translational Medicine, Cell Therapy +8

Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma

Guillemette Fouquet, Stéphanie Guidez, Charles Herbaux et al. · Clinical Cancer Research · 2014 · 73 citations · Full text

Monitoring <scp>CAR</scp> T‐cells using flow cytometry

Julie Demaret, Pauline Varlet, Jacques Trauet et al. · Cytometry Part B Clinical Cytometry · 2020 · 71 citations · Full text